Indication*

Diagnosis of primary hyperaldosteronism. Short-term per-op treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are poor operative risks or who decline surgery & or for patients with bilateral micro-or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). CHF, including severe heart failure (NYHA class III-IV) to increase survival & reduce the risk of hospitalization when used in addition to standard therapy. Liver cirrhosis accompanied by edema & or ascites. Nephrotic syndrome . Essential HTN. Treatment & prophylaxis of hypokalemia.

Directions for Use*

Primary hyperaldosteronism Long test: 400 mg daily for 3-4 week. Short test: 400 mg daily for 4 days. Pre-op: 100-400 mg daily. Edema in adult with CHF, hepatic cirrhosis or nephrotic syndrome Initially 100 mg in single or divided doses or 25-200 mg daily. Sole agent for diuresis: Continued for at least 5 days at the initial dosage level, may be adjusted to the optimal therapeutic or maintenance level administered in either single or divided daily doses. Essential HTN Initially 50-100 mg in single or divided doses, Hypokalemia 25-100 mg daily. Severe heart failure (NYHA class III-IV) Patient with serum K

Administration*

Should be taken with food.

*written indications, directions, and administration are updated as of January 22, 2024 and may not be accurate with the actual product purchased. Please read the details in the packaging.

Share

Share

Link

Close share Copy link

View full details